NASDAQ:INMB INmune Bio (INMB) Stock Price, News & Analysis $5.85 -0.10 (-1.68%) (As of 10/31/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About INmune Bio Stock (NASDAQ:INMB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get INmune Bio alerts:Sign Up Key Stats Today's Range$5.67▼$5.9850-Day Range$4.83▼$7.0652-Week Range$4.78▼$14.74Volume168,812 shsAverage Volume163,310 shsMarket Capitalization$115.60 millionP/E RatioN/ADividend YieldN/APrice Target$20.00Consensus RatingBuy Company OverviewINmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.Read More… top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… INmune Bio Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks50th Percentile Overall ScoreINMB MarketRank™: INmune Bio scored higher than 50% of companies evaluated by MarketBeat, and ranked 627th out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingINmune Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageINmune Bio has only been the subject of 3 research reports in the past 90 days.Read more about INmune Bio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for INmune Bio are expected to grow in the coming year, from ($2.14) to ($1.58) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of INmune Bio is -2.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of INmune Bio is -2.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioINmune Bio has a P/B Ratio of 2.83. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about INmune Bio's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.32% of the outstanding shares of INmune Bio have been sold short.Short Interest Ratio / Days to CoverINmune Bio has a short interest ratio ("days to cover") of 12.6, which indicates bearish sentiment.Change versus previous monthShort interest in INmune Bio has recently increased by 5.60%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldINmune Bio does not currently pay a dividend.Dividend GrowthINmune Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted14.32% of the outstanding shares of INmune Bio have been sold short.Short Interest Ratio / Days to CoverINmune Bio has a short interest ratio ("days to cover") of 12.6, which indicates bearish sentiment.Change versus previous monthShort interest in INmune Bio has recently increased by 5.60%, indicating that investor sentiment is decreasing significantly. News and Social Media2.8 / 5News Sentiment0.08 News SentimentINmune Bio has a news sentiment score of 0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for INmune Bio this week, compared to 2 articles on an average week.Search Interest3 people have searched for INMB on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows2 people have added INmune Bio to their MarketBeat watchlist in the last 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, INmune Bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $200,087.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders35.20% of the stock of INmune Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 12.72% of the stock of INmune Bio is held by institutions.Read more about INmune Bio's insider trading history. Receive INMB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for INmune Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address INMB Stock News HeadlinesINmune Bio, Inc. (NASDAQ:INMB) CFO David J. Moss Acquires 10,000 SharesOctober 1, 2024 | insidertrades.comINmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business UpdateOctober 31 at 4:05 PM | globenewswire.comtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.October 31, 2024 | Traders Agency (Ad)INmune Bio Inc (INMB) Q3 2024 Earnings Report Preview: What To Look ForOctober 30 at 1:17 PM | finance.yahoo.comINmune Bio to host webinar on cognitive testing using EMACC, CDR-SBOctober 29 at 3:56 AM | markets.businessinsider.comINmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SBOctober 28 at 8:00 AM | globenewswire.comHighbridge Capital Management's Strategic Acquisition of INmune Bio Inc SharesOctober 25, 2024 | finance.yahoo.comINmune Bio announces publication of XPro1595 data in Cell ReportsOctober 25, 2024 | markets.businessinsider.comSee More Headlines INMB Stock Analysis - Frequently Asked Questions How have INMB shares performed this year? INmune Bio's stock was trading at $11.26 at the beginning of the year. Since then, INMB stock has decreased by 48.0% and is now trading at $5.85. View the best growth stocks for 2024 here. How were INmune Bio's earnings last quarter? INmune Bio, Inc. (NASDAQ:INMB) posted its earnings results on Thursday, August, 1st. The company reported ($0.50) EPS for the quarter, beating analysts' consensus estimates of ($0.63) by $0.13. INmune Bio had a negative net margin of 26,333.59% and a negative trailing twelve-month return on equity of 103.56%. Who are INmune Bio's major shareholders? Top institutional investors of INmune Bio include Fermata Advisors LLC (0.22%) and Financial Advocates Investment Management (0.07%). Insiders that own company stock include Raymond Joseph Tesi, David J Moss, Timothy J Schroeder, Scott Juda and Mark William Lowdell. View institutional ownership trends. How do I buy shares of INmune Bio? Shares of INMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of INmune Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that INmune Bio investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), ServiceNow (NOW) and Netflix (NFLX). Company Calendar Last Earnings8/01/2024Today10/31/2024Next Earnings (Confirmed)10/31/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:INMB CUSIPN/A CIK1711754 Webwww.inmunebio.com Phone(858) 964-3720FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Stock Price Target$20.00 High Stock Price Target$22.00 Low Stock Price Target$18.00 Potential Upside/Downside+241.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,010,000.00 Net Margins-26,333.59% Pretax Margin-44,402.35% Return on Equity-103.56% Return on Assets-68.94% Debt Debt-to-Equity RatioN/A Current Ratio2.36 Quick Ratio2.36 Sales & Book Value Annual Sales$85,000.00 Price / Sales1,360.02 Cash FlowN/A Price / Cash FlowN/A Book Value$2.07 per share Price / Book2.83Miscellaneous Outstanding Shares19,761,000Free Float12,805,000Market Cap$115.60 million OptionableOptionable Beta1.85 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:INMB) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding INmune Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share INmune Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.